Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Scientists at Monash University in Australia developed AOD 9604 in the 1990s specifically as an anti-obesity treatment
0.22 m) immediately prior to use Aliquot and store reconstituted solutions at 20 C (or lower) to minimise degradation Avoid repeated freezethaw cycles Due to reported low intrinsic stability in vitro, prepare fresh working solutions when possible Specifications Summary Precautions & Notes Experimental behaviour of DSIP is dependent on concentration, exposure duration, and model system Buffer composition, pH, and enzymatic activity may influence peptide stability Due to reported rapid degradation in some in vitro systems, appropriate controls are recommended Literature reports describe heterogeneous and sometimes contradictory findings across models Intended strictly for laboratory research use
Related Link: IV Therapy Benefits: What to Know for Your Health
Clinical Relevance and Human Trials Clinical trials have explored the administration of BPC 157 at a dosage of 200 g per person per day via intramuscular injection for a duration of 7 days
